Clinical Trial Update: A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating aleglitazar as monotherapy in drug-naïve patients with Type 2 diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Aleglitazar (Aleglitazar)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diabetes Mellitus Type 2 | Phase 3 | Status: COMPLETED